E
Eric Siemers
Researcher at Eli Lilly and Company
Publications - 153
Citations - 24600
Eric Siemers is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Solanezumab & Dementia. The author has an hindex of 44, co-authored 145 publications receiving 19862 citations. Previous affiliations of Eric Siemers include Indiana University.
Papers
More filters
Journal ArticleDOI
The Integrated Alzheimer's Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial.
TL;DR: iADRS was the only tool that consistently differentiated between solanezumab and placebo groups, and is a useful integrated measurement tool for treatment trials of individuals with mild AD dementia.
Journal ArticleDOI
The A4 trial: Anti-amyloid treatment of asymptomatic Alzheimer's disease
Reisa A. Sperling,Ann Catherine Downing,David P. Salmon,Dorene M. Rentz,Eric Siemers,Gopalan Sethuraman,Jason Karlawish,Keith A. Johnson,Michael C. Donohue,Paul S. Aisen +9 more
Journal ArticleDOI
Global issues in drug development for Alzheimer's disease
Rachelle S. Doody,Patricia E. Cole,David S. Miller,Eric Siemers,Ronald Black,Howard Feldman,Rachel Schindler,Stephen M. Graham,Theresa Heath,Ara S. Khachaturian,Rebecca Evans,Maria C. Carrillo +11 more
TL;DR: The cultural and ethical context of global clinical trials, potential benefits for those involved, and practical approaches to obstacles generated by these global trials were discussed at a meeting of the Alzheimer's Association Research Roundtable.
Journal ArticleDOI
Incidence and clinical progression of placebo-treated amyloid-negative subjects with mild-to-moderate Alzheimer's disease (AD): Results from the phase III PET substudies of bapineuzumab and solanezumab
Stephen Salloway,Reisa A. Sperling,Gregg Keith M,Peng Yu,Abhinay D. Joshi,Ming Lu,Mark A. Mintun,Michael J. Pontecorvo,Kevin Booth,Bradley T. Wyman,Jia Sun,Karen Sundell,Mark E. Schmidt,Richard Margolin,Daniel Skovronsky,Enchi Liu,Eric Siemers,Robert H. Brashear +17 more
Journal ArticleDOI
Expectations and clinical meaningfulness of randomized controlled trials
Ronald C. Petersen,Paul S. Aisen,Josh Andrews,Alireza Atri,Brandy R. Matthews,Dorene M. Rentz,Eric Siemers,Christopher J. Weber,Maria C. Carrillo +8 more
TL;DR: In this paper , the Alzheimer's Association convened a work group of experts to discuss key considerations for interpreting data from cognitive and functional measures and what is considered a clinically meaningful benefit or meaningful slowing of this fatal disease.